To access the cost and effectiveness of Aripiprazole treatment in schizophrenia patients using gene based markers
Phase 2
- Conditions
- Health Condition 1: F209- Schizophrenia, unspecified
- Registration Number
- CTRI/2023/09/057176
- Lead Sponsor
- AJIITH XAVIER F
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Schizophrenia patients who will be started on aripiprazole therapy
2.Patients >16 years of either gender
3.Patient or legally authorized representative willing to give informed consent
Exclusion Criteria
1.Patients with chronic liver or kidney disease
2.Pregnant and lactating females
3. History of neurological, neuroendocrine, or other medical conditions known to affect the central nervous system.
4. Any significant medical condition that has clinically significant interaction with aripiprazole
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse Effect & therapeutic outcomes with aripiprazole therapeutic regimen based on pharmacogenomic profilingTimepoint: one & three months
- Secondary Outcome Measures
Name Time Method 1.The cost-benefit & conceptual model for personalized medicine and therapeutic OPD for aripiprazole <br/ ><br>2.Proposed dose based on genetic polymorphism for CYP3A4, DRD2 and 5HTR2A <br/ ><br>Timepoint: one & three months